Feb 6, 2025 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
Jan 17, 2025 7:00 am EST Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
Jan 12, 2025 6:00 pm EST Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
Jan 6, 2025 7:00 am EST Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
Dec 23, 2024 7:00 am EST Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
Dec 19, 2024 7:00 am EST Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2024 7:00 am EST Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
Nov 20, 2024 7:00 am EST Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Nov 19, 2024 7:00 am EST Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
Nov 8, 2024 7:00 am EST Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
